← All trials
NCT06658353
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2024
- Primary completion
- Dec 30, 2026
- Completion date
- Dec 30, 2026
- First posted
- Oct 26, 2024
- Last posted
- Oct 26, 2024
- Enrollment
- 54
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu vcare pharmaceutical technology co., LTDLead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.